{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T22:17:37Z","timestamp":1776377857938,"version":"3.51.2"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.neuropharm.2018.10.039","type":"journal-article","created":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T16:55:15Z","timestamp":1540832115000},"page":"233-243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["S-ketamine reduces marble burying behaviour: Involvement of ventromedial orbitofrontal cortex and AMPA receptors"],"prefix":"10.1016","volume":"144","author":[{"given":"Cristina Luz","family":"Tosta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela Pandini","family":"Silote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Paula","family":"Fracalossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariandra Guerini","family":"Sartim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Andreatini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e2mia Regiane Louren\u00e7o","family":"Joca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Beijamini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2018.10.039_bib1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pharmthera.2018.05.010","article-title":"The neurobiology of depression, ketamine and rapid-acting antidepressants: is it glutamate inhibition or activation?","volume":"190","author":"Abdallah","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/JCP.0b013e318192e9a4","article-title":"Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial","volume":"29","author":"Aboujaoude","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0022-3956(00)00022-4","article-title":"fMRI of neuronal activation with symptom provocation in unmedicated patients with obsessive compulsive disorder","volume":"34","author":"Adler","year":"2000","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib4","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/da.22367","article-title":"Dissecting OCD circuits: from animal models to targeted treatments","volume":"32","author":"Ahmari","year":"2015","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib5","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1126\/science.1234733","article-title":"Repeated cortico-striatal stimulation generates persistent OCD-like behavior","volume":"340","author":"Ahmari","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00213-010-1808-9","article-title":"The role of NMDA receptors in the signal attenuation rat model of obsessive-compulsive disorder","volume":"210","author":"Albelda","year":"2010","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.neubiorev.2011.04.006","article-title":"Animal models of obsessive-compulsive disorder: exploring pharmacology and neural substrates","volume":"36","author":"Albelda","year":"2012","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib8","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib9","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.brainresbull.2016.01.013","article-title":"NMDA receptor antagonists attenuate the proconvulsant effect of juvenile social isolation in male mice","volume":"121","author":"Amiri","year":"2016","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1476-5381.1983.tb11031.x","article-title":"The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate","volume":"79","author":"Anis","year":"1983","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib11","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s00213-004-1847-1","article-title":"Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study","volume":"174","author":"Arnold","year":"2004","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib12","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/archpsyc.63.7.769","article-title":"Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder","volume":"63","author":"Arnold","year":"2006","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1440-1819.2005.01426.x","article-title":"Plasma nitrate values in patients with obsessive-compulsive disorder","volume":"59","author":"Atmaca","year":"2005","journal-title":"Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/13651501.2012.667114","article-title":"Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care","volume":"16","author":"Bandelow","year":"2012","journal-title":"Int. J. Psychiatr. Clin. Pract."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib17","doi-asserted-by":"crossref","first-page":"S616","DOI":"10.1016\/S0924-977X(16)31701-1","article-title":"Rapid and sustained anticompulsive effect of ketamine in mice submitted to the marble burying test","volume":"26","author":"Beijamini","year":"2016","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib19","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/npp.2009.77","article-title":"Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder","volume":"34","author":"Bhattacharyya","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1176\/appi.neuropsych.15090213","article-title":"The effect of intravenous citalopram on the neural substrates of obsessive-compulsive disorder","volume":"28","author":"Bhikram","year":"2016","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.comppsych.2017.04.002","article-title":"Comorbidity, age of onset and suicidality in obsessive-compulsive disorder (OCD): an international collaboration","volume":"76","author":"Brakoulias","year":"2017","journal-title":"Compr. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib22","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archpsyc.1996.01830070041008","article-title":"Functional magnetic resonance imaging of symptom provocation in obsessive-compulsive disorder","volume":"53","author":"Breiter","year":"1996","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib23","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1126\/science.1232380","article-title":"Optogenetic stimulation of lateral orbitofronto-striatal pathway suppresses compulsive behaviors","volume":"340","author":"Burgui\u00e8re","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/FBP.0b013e32833b33c5","article-title":"Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors","volume":"21","author":"Casarotto","year":"2010","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib25","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/sj.npp.1300733","article-title":"Glutamatergic dysfunction in OCD","volume":"30","author":"Chakrabarty","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib26","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1126\/science.1154433","article-title":"Orbitofrontal dysfunction in patients with obsessive-compulsive disorder and their unaffected relatives","volume":"321","author":"Chamberlain","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jpsychires.2003.08.001","article-title":"Left anterior subregion of orbitofrontal cortex volume reduction and impaired organizational strategies in obsessive-compulsive disorder","volume":"38","author":"Choi","year":"2004","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib28","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.yhbeh.2006.06.007","article-title":"Increased anxiety-like behavior during the post-stress period in mice exposed to repeated restraint stress","volume":"50","author":"Chotiwat","year":"2006","journal-title":"Horm. Behav."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1017\/S1092852913000564","article-title":"Animal models of obsessive-compulsive spectrum disorders","volume":"19","author":"D'Angelo","year":"2014","journal-title":"CNS Spectr."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib30","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1523\/JNEUROSCI.14-09-05147.1994","article-title":"Gases as biological messengers: nitric oxide and carbon monoxide in the brain","volume":"14","author":"Dawson","year":"1994","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib31","doi-asserted-by":"crossref","first-page":"7062","DOI":"10.1007\/s12035-018-0902-6","article-title":"Elastase-2 knockout mice display anxiogenic- and antidepressant-like phenotype: putative role for BDNF metabolism in prefrontal cortex","volume":"55","author":"Diniz","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib32","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/ALN.0b013e3181ed09a2","article-title":"Taming the ketamine tiger","volume":"113","author":"Domino","year":"2010","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib33","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1007\/s00213-016-4327-5","article-title":"Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression","volume":"233","author":"du Jardin","year":"2016","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib34","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejphar.2008.01.035","article-title":"Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive-compulsive disorder","volume":"586","author":"Egashira","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib35","first-page":"896","article-title":"Obsessive-compulsive disorder: diagnosis and management","volume":"92","author":"Fenske","year":"2015","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jpsychires.2018.02.006","article-title":"Anxiolytic effects of ascorbic acid and ketamine in mice","volume":"100","author":"Fraga","year":"2018","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib37","doi-asserted-by":"crossref","first-page":"8106","DOI":"10.1073\/pnas.1414728112","article-title":"Optogenetic stimulation of infralimbic PFC reproduces ketamine's rapid and sustained antidepressant actions","volume":"112","author":"Fuchikami","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib38","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/npp.2015.233","article-title":"The antidepressant effects of an mGlu2\/3 receptor antagonist and ketamine require AMPA receptor stimulation in the mPFC and subsequent activation of the 5-HT neurons in the DRN","volume":"41","author":"Fukumoto","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib39","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1007\/s00213-013-3378-0","volume":"231","author":"Fukumoto","year":"2014","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib40","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejphar.2015.11.044","article-title":"Involvement of nitric oxide in anticompulsive-like effect of agmatine on marble-burying behaviour in mice","volume":"770","author":"Gawali","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib41","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10334-013-0427-y","article-title":"Neurochemicals measured by 1H-MR spectroscopy: putative vulnerability biomarkers for obsessive compulsive disorder","volume":"27","author":"Gnanavel","year":"2014","journal-title":"Magn. Reson. Mater. Phys., Biol. Med."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib42","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1001\/archpsyc.1995.03950130053006","article-title":"Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis","volume":"52","author":"Greist","year":"1995","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib43","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jama.2017.2200","article-title":"Obsessive-compulsive disorder: advances in diagnosis and treatment","volume":"317","author":"Hirschtritt","year":"2017","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib44","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/17460441.2018.1417379","article-title":"Lost in translation? A critical look at the role that animal models of obsessive compulsive disorder play in current drug discovery strategies","volume":"13","author":"Hoffman","year":"2018","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib45","doi-asserted-by":"crossref","first-page":"11496","DOI":"10.1523\/JNEUROSCI.2213-07.2007","article-title":"NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons","volume":"27","author":"Homayoun","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1254\/jjp.68.65","article-title":"5-HT1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice","volume":"68","author":"Ichimaru","year":"1995","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib47","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neulet.2009.12.048","article-title":"Effects of agents targeting glutamatergic systems on marble-burying behavior","volume":"471","author":"Iijima","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib48","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/FBP.0b013e32834afebe","article-title":"Pharmacological evaluation of the adequacy of marble burying as an animal model of compulsion and\/or anxiety","volume":"22","author":"Jimenez-Gomez","year":"2011","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0006-8993(97)00810-X","article-title":"Modulation of anxiety-related behaviours following lesions of the prelimbic or infralimbic cortex in the rat","volume":"772","author":"Jinks","year":"1997","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib50","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.neuroscience.2004.08.037","article-title":"Role of the orbital cortex and of the serotonergic system in a rat model of obsessive compulsive disorder","volume":"130","author":"Joel","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib51","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10519-010-9339-z","article-title":"Symptom dimensions in OCD: item-level factor analysis and heritability estimates","volume":"40","author":"Katerberg","year":"2010","journal-title":"Behav. Genet."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib52","first-page":"1186","article-title":"Ketamine: teaching an old drug new tricks","volume":"87","author":"Kohrs","year":"1998","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib53","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bbr.2014.05.065","article-title":"Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats","volume":"271","author":"Koike","year":"2014","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib54","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bbr.2011.05.035","article-title":"Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression","volume":"224","author":"Koike","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib55","series-title":"Guideline Watch (March 2013): Practice Guideline for the Treatment of Patients with Obsessive-compulsive Disorder","author":"Koran","year":"2013"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib56","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9131680","article-title":"Changes of nitric oxide and peroxynitrite serum levels during drug therapy in patients with obsessive-compulsive disorder","author":"Kouti","year":"2016","journal-title":"Adv. Med."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib57","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.neulet.2010.06.002","article-title":"Nitric oxide is involved in the regulation of marble-burying behavior","volume":"480","author":"Krass","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib58","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1017\/neu.2014.39","article-title":"Nitric oxide involvement in the antidepressant-like effect of ketamine in the Flinders sensitive line rat model of depression","volume":"27","author":"Liebenberg","year":"2014","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib59","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","article-title":"Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors","volume":"63","author":"Maeng","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib60","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0091-3057(92)90169-G","article-title":"Serotonin 5-HT1A receptor-mediated hypothermia in mice: absence of spare receptors and rapid induction of tolerance","volume":"43","author":"Meller","year":"1992","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib61","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1001\/jamapsychiatry.2013.914","article-title":"Deficits in conditioned fear extinction in obsessive-compulsive disorder and neurobiological changes in the fear circuit","volume":"70","author":"Milad","year":"2013","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib62","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib63","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/00004583-199806000-00017","article-title":"Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder","volume":"37","author":"Moore","year":"1998","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib64","series-title":"The Global Burden of Disease: a Comprehensive Assessment of Mortality and Disability from Deseases, Injuries and Risk Factors in 1990 and Projected to 2010","author":"Murray","year":"1996"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib65","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejphar.2006.07.015","article-title":"A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants","volume":"547","author":"Nicolas","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib66","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1017\/S1461145714000649","article-title":"Raphe AMPA receptors and nicotinic acetylcholine receptors mediate ketamine-induced serotonin release in the rat prefrontal cortex","volume":"17","author":"Nishitani","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib67","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0091-3057(91)90590-X","article-title":"Evaluation of marble-burying behavior as a model of anxiety","volume":"38","author":"Njung\u2019e","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib68","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1476-5381.1991.tb12392.x","article-title":"Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents","volume":"104","author":"Njung\u2019e","year":"1991","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib69","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.neulet.2014.01.015","article-title":"Effects of ketamine and N-methyl-D-aspartate on fluoxetine-induced antidepressant-related behavior using the forced swimming test","volume":"566","author":"Owolabi","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib70","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nrn3746","article-title":"Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective","volume":"15","author":"Pauls","year":"2014","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib71","series-title":"The Mouse Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2001"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib72","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.neuropharm.2016.05.010","article-title":"Ketamine treatment involves medial prefrontal cortex serotonin to induce a rapid antidepressant-like activity in BALB\/cJ mice","volume":"112","author":"Pham","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib73","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.pharmthera.2011.09.006","article-title":"Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment","volume":"132","author":"Pittenger","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib74","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/S0006-3223(03)00183-5","article-title":"Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder","volume":"54","author":"Pogarell","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib75","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s12640-017-9759-0","article-title":"Comparison of the psychopharmacological effects of tiletamine and ketamine in rodents","volume":"32","author":"Popik","year":"2017","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib76","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1176\/appi.ajp.162.11.2191-a","article-title":"Memantine for treatment-resistant OCD","volume":"162","author":"Poyurovsky","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib77","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0014-2999(03)01272-X","article-title":"The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review","volume":"463","author":"Prut","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib78","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/npp.2015.20","article-title":"Enhancement of fear extinction with deep brain stimulation: evidence for medial orbitofrontal involvement","volume":"40","author":"Rodriguez-Romaguera","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib79","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/npp.2013.150","article-title":"Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept","volume":"38","author":"Rodriguez","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib80","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/00004583-200009000-00008","article-title":"Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine","volume":"39","author":"Rosenberg","year":"2000","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib81","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.biopsych.2009.10.007","article-title":"Anatomical alterations and symptom-related functional activity in obsessive-compulsive disorder are correlated in the lateral orbitofrontal cortex","volume":"67","author":"Rotge","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib82","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1080\/0004867010060519","article-title":"Bilateral orbitomedial leucotomy for obsessive-compulsive disorder: a single-case study using positron emission tomography","volume":"35","author":"Sachdev","year":"2001","journal-title":"Aust. N. Z. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib83","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.pbb.2014.04.007","article-title":"Experimental evidence for involvement of nitric oxide in low frequency magnetic field induced obsessive compulsive disorder-like behavior","volume":"122","author":"Salunke","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib84","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0893-133X(99)00082-2","article-title":"Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder","volume":"21","author":"Saxena","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib85","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00406-016-0718-1","article-title":"Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression","volume":"267","author":"Shirayama","year":"2017","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib86","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2147\/NDT.S163946","article-title":"Association of serotonin receptor 2a haplotypes with obsessive-compulsive disorder and its treatment response in Iranian patients: a genetic and pharmacogenetic study","volume":"14","author":"Sina","year":"2018","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib87","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1586\/14737175.2014.963057","article-title":"The reappraisal of benzodiazepines in the treatment of anxiety and related disorders","volume":"14","author":"Starcevic","year":"2014","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib88","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/WNF.0000000000000029","article-title":"Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs - an open-label study","volume":"37","author":"Stryjer","year":"2014","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib89","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archpsyc.56.10.913","article-title":"Orbital frontal and amygdala volume reductions in obsessive-compulsive disorder","volume":"56","author":"Szeszko","year":"1999","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib90","doi-asserted-by":"crossref","first-page":"254","DOI":"10.21307\/ane-2017-059","article-title":"Marble burying as compulsive behaviors in male and female mice","volume":"77","author":"Taylor","year":"2017","journal-title":"Acta Neurobiol. Exp. (Wars)"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib91","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00213-009-1466-y","article-title":"Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety","volume":"204","author":"Thomas","year":"2009","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib92","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/08039488.2016.1240230","article-title":"Neuronal nitric oxide synthase polymorphisms in obsessive-compulsive disorder","volume":"71","author":"Topaloglu","year":"2017","journal-title":"Nord. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib93","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.niox.2009.07.001","article-title":"Role of nitric oxide in obsessive-compulsive behavior and its involvement in the anti-compulsive effect of paroxetine in mice","volume":"21","author":"Umathe","year":"2009","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib94","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/j.neuropharm.2011.12.030","article-title":"Endocannabinoid analogues exacerbate marble-burying behavior in mice via TRPV1 receptor","volume":"62","author":"Umathe","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib95","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/nature06104","article-title":"Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice","volume":"448","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib96","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pscychresns.2005.12.006","article-title":"A magnetic resonance spectroscopy investigation of obsessive-compulsive disorder and anxiety","volume":"146","author":"Whiteside","year":"2006","journal-title":"Psychiatry Res. Neuroimaging."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib97","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3758\/s13415-016-0413-8","article-title":"Of mice and marbles: novel perspectives on burying behavior as a screening test for psychiatric illness","volume":"16","author":"Wolmarans","year":"2016","journal-title":"Cognit. Affect Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib98","series-title":"Pharmacological Treatment of Mental Disorders in Primary Health Care","author":"World Health Organization","year":"2009"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib99","doi-asserted-by":"crossref","first-page":"e632","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.10.039_bib100","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","author":"Zanos","year":"2018","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib101","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib102","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pbb.2013.05.010","article-title":"Inhibition of the L-arginine-nitric oxide pathway mediates the antidepressant effects of ketamine in rats in the forced swimming test","volume":"110","author":"Zhang","year":"2013","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib103","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pbb.2013.11.033","article-title":"R(\u2212)-ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine","volume":"116","author":"Zhang","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2018.10.039_bib104","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.neuroscience.2016.09.012","article-title":"Rodent models of obsessive compulsive disorder: evaluating validity to interpret emerging neurobiology","volume":"345","author":"Zike","year":"2017","journal-title":"Neuroscience"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818304829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818304829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T21:21:30Z","timestamp":1662326490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818304829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":103,"alternative-id":["S0028390818304829"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.10.039","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"S-ketamine reduces marble burying behaviour: Involvement of ventromedial orbitofrontal cortex and AMPA receptors","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.10.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}